Aurinia Pharmaceuticals (AUPH) Tops Q1 EPS by 7c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Aurinia Pharmaceuticals (AUPH) PT Lowered to $6 at Jefferies
May 2, 2024 4:28 PM EDTJefferies analyst Maury Raycroft lowered the price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) to $6.00 (from $9.00) while maintaining a Hold rating.
The analyst comments "AUPH's strong PSFs (w/ pt restarts) bodes well w/ $200-220M rev guidance. 2Q sales should provide... More



